Logo image of NTLA

INTELLIA THERAPEUTICS INC (NTLA) Stock Fundamental Analysis

NASDAQ:NTLA - Nasdaq - US45826J1051 - Common Stock - Currency: USD

10.965  +0.22 (+2.09%)

Fundamental Rating

3

Taking everything into account, NTLA scores 3 out of 10 in our fundamental rating. NTLA was compared to 550 industry peers in the Biotechnology industry. The financial health of NTLA is average, but there are quite some concerns on its profitability. While showing a medium growth rate, NTLA is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NTLA has reported negative net income.
In the past year NTLA has reported a negative cash flow from operations.
In the past 5 years NTLA always reported negative net income.
In the past 5 years NTLA always reported negative operating cash flow.
NTLA Yearly Net Income VS EBIT VS OCF VS FCFNTLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M -400M -500M

1.2 Ratios

NTLA has a Return On Assets of -53.33%. This is comparable to the rest of the industry: NTLA outperforms 47.64% of its industry peers.
NTLA has a Return On Equity (-67.43%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -53.33%
ROE -67.43%
ROIC N/A
ROA(3y)-37.25%
ROA(5y)-30.46%
ROE(3y)-47.91%
ROE(5y)-38.99%
ROIC(3y)N/A
ROIC(5y)N/A
NTLA Yearly ROA, ROE, ROICNTLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NTLA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NTLA Yearly Profit, Operating, Gross MarginsNTLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K

More info and screens

6

2. Health

2.1 Basic Checks

NTLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NTLA has more shares outstanding
Compared to 5 years ago, NTLA has more shares outstanding
There is no outstanding debt for NTLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NTLA Yearly Shares OutstandingNTLA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
NTLA Yearly Total Debt VS Total AssetsNTLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of -1.25, we must say that NTLA is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.25, NTLA perfoms like the industry average, outperforming 58.73% of the companies in the same industry.
NTLA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.25
ROIC/WACCN/A
WACC9.77%
NTLA Yearly LT Debt VS Equity VS FCFNTLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

A Current Ratio of 4.90 indicates that NTLA has no problem at all paying its short term obligations.
NTLA's Current ratio of 4.90 is in line compared to the rest of the industry. NTLA outperforms 52.91% of its industry peers.
A Quick Ratio of 4.90 indicates that NTLA has no problem at all paying its short term obligations.
NTLA has a Quick ratio (4.90) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.9
Quick Ratio 4.9
NTLA Yearly Current Assets VS Current LiabilitesNTLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 14.23% over the past year.
Looking at the last year, NTLA shows a very negative growth in Revenue. The Revenue has decreased by -37.19% in the last year.
Measured over the past years, NTLA shows a small growth in Revenue. The Revenue has been growing by 6.07% on average per year.
EPS 1Y (TTM)14.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.87%
Revenue 1Y (TTM)-37.19%
Revenue growth 3Y20.53%
Revenue growth 5Y6.07%
Sales Q2Q%104.83%

3.2 Future

Based on estimates for the next years, NTLA will show a very strong growth in Earnings Per Share. The EPS will grow by 30.37% on average per year.
The Revenue is expected to grow by 106.03% on average over the next years. This is a very strong growth
EPS Next Y18.93%
EPS Next 2Y10.65%
EPS Next 3Y8.98%
EPS Next 5Y30.37%
Revenue Next Year5.54%
Revenue Next 2Y-3.5%
Revenue Next 3Y8.78%
Revenue Next 5Y106.03%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NTLA Yearly Revenue VS EstimatesNTLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B 2.5B
NTLA Yearly EPS VS EstimatesNTLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 -10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NTLA. In the last year negative earnings were reported.
Also next year NTLA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NTLA Price Earnings VS Forward Price EarningsNTLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NTLA Per share dataNTLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.65%
EPS Next 3Y8.98%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NTLA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTELLIA THERAPEUTICS INC

NASDAQ:NTLA (8/12/2025, 11:02:08 AM)

10.965

+0.22 (+2.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners92.87%
Inst Owner Change0.36%
Ins Owners1.43%
Ins Owner Change2.03%
Market Cap1.14B
Analysts80.59
Price Target36.54 (233.24%)
Short Float %29.43%
Short Ratio5.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.12%
Min EPS beat(2)6.34%
Max EPS beat(2)15.91%
EPS beat(4)3
Avg EPS beat(4)1.61%
Min EPS beat(4)-20.94%
Max EPS beat(4)15.91%
EPS beat(8)6
Avg EPS beat(8)4.23%
EPS beat(12)9
Avg EPS beat(12)3.3%
EPS beat(16)9
Avg EPS beat(16)-7.28%
Revenue beat(2)2
Avg Revenue beat(2)42.61%
Min Revenue beat(2)37.29%
Max Revenue beat(2)47.93%
Revenue beat(4)3
Avg Revenue beat(4)8.63%
Min Revenue beat(4)-64.41%
Max Revenue beat(4)47.93%
Revenue beat(8)5
Avg Revenue beat(8)8.91%
Revenue beat(12)9
Avg Revenue beat(12)12.83%
Revenue beat(16)11
Avg Revenue beat(16)10.69%
PT rev (1m)-8.53%
PT rev (3m)-14.02%
EPS NQ rev (1m)0.47%
EPS NQ rev (3m)11.24%
EPS NY rev (1m)0%
EPS NY rev (3m)11.47%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.39%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.73%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 24.92
P/FCF N/A
P/OCF N/A
P/B 1.46
P/tB 1.46
EV/EBITDA N/A
EPS(TTM)-4.7
EYN/A
EPS(NY)-4.07
Fwd EYN/A
FCF(TTM)-3.68
FCFYN/A
OCF(TTM)-3.64
OCFYN/A
SpS0.44
BVpS7.53
TBVpS7.53
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -53.33%
ROE -67.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-37.25%
ROA(5y)-30.46%
ROE(3y)-47.91%
ROE(5y)-38.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 39.01%
Cap/Sales 8.79%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.9
Quick Ratio 4.9
Altman-Z -1.25
F-Score3
WACC9.77%
ROIC/WACCN/A
Cap/Depr(3y)130.37%
Cap/Depr(5y)126.64%
Cap/Sales(3y)24.85%
Cap/Sales(5y)23.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.87%
EPS Next Y18.93%
EPS Next 2Y10.65%
EPS Next 3Y8.98%
EPS Next 5Y30.37%
Revenue 1Y (TTM)-37.19%
Revenue growth 3Y20.53%
Revenue growth 5Y6.07%
Sales Q2Q%104.83%
Revenue Next Year5.54%
Revenue Next 2Y-3.5%
Revenue Next 3Y8.78%
Revenue Next 5Y106.03%
EBIT growth 1Y39.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.82%
EBIT Next 3Y5.08%
EBIT Next 5Y13.51%
FCF growth 1Y-0.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.95%
OCF growth 3YN/A
OCF growth 5YN/A